Chinese drug sector’s stature grows at major cancer conference
An array of Chinese drug makers showcased positive trial results for new cancer treatments at a major European medical conference, underscoring the expanding international influence of China’s biotech sector. Domestic innovative drugs, particularly antibody-drug conjugates (ADCs), delivered impressive data across multiple tumour types at the European Society for Medical Oncology (Esmo) Congress,…
Chinese drug manufacturers showcased promising trial results for new cancer treatments at the European Society for Medical Oncology (Esmo) Congress, highlighting the growing international influence of China's biotech sector. Among the 96 late-breaking abstracts presented, Chinese research accounted for 29, with five of the 12 studies selected for the prestigious presidential symposium.
Notable successes include Sichuan Kelun-Biotech Biopharmaceutical's ADC drug sacituzumab tirumotecan (sac-TMT), which showed a 32% reduction in the risk of death for patients with advanced or recurrent endometrial cancer. Additionally, Hansoh Pharmaceutical's bone cancer drug risvutatug rezetecan (Ris-Rez) demonstrated a 67% reduction in disease progression or death for patients with progressed or relapsed osteosarcoma.
While not all Chinese firms fared well, the conference provided significant validation for several innovative cancer treatments.
Brief written by urgent.news from SCMP Business's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
